VLA1601 + Placebo
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 23/100
23
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Zika Virus
Conditions
Zika Virus, Zika Virus Infection
Trial Timeline
Feb 24, 2018 → Nov 16, 2018
NCT ID
NCT03425149About VLA1601 + Placebo
VLA1601 + Placebo is a phase 1 stage product being developed by Valneva SE for Zika Virus. The current trial status is completed. This product is registered under clinical trial identifier NCT03425149. Target conditions include Zika Virus, Zika Virus Infection.
Hype Score Breakdown
Clinical
6
Activity
8
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03425149 | Phase 1 | Completed |
Competing Products
5 competing products in Zika Virus
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| mRNA-1893 | Moderna | Phase 1 | 0 |
| mRNA-1325 | Moderna | Phase 1 | 0 |
| mRNA-1893 | Moderna | Phase 2 | 0 |
| VLA1601 + CpG 1018® + 3M-052-AF | Valneva SE | Phase 1 | 23 |
| Zika Virus Immune Globulin (ZIKV-IG) | Emergent BioSolutions | Phase 1 | 19 |